- Home
- News
- latamerica
- antibiotic release
Antibiotic Release Articles & Analysis
5 news found
BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, today announced that the company has submitted a supplementary De Novo application to the US Food and Drug Administration (FDA) to obtain a market approval for the company’s antibiotic-releasing product CERAMENT® G. The application is specified for the ...
The company’s lead product in development is called LDGraft, and is a low dose, controlled release rhBMP-2 for the treatment of degenerative disc disease. In September 2020, Locate Bio in-licensed multiple late-stage orthobiologics assets from the Royal College of Surgeons in Ireland’s (RCSI) University of Medicine and Health Sciences. ...
CognitOss is a drug-device combination product for the treatment of chronic infections within bone. It has a unique antibiotic release profile, targeting both improvements in the elimination of infection, and the regeneration of bone at the infection site. ...
CognitOss is intended to offer surgeons a single surgical procedure alternative, combining a fully resorbable bone graft with best-in-class bone healing properties and a proprietary dual-phasic release of antibiotics, to initially provide a bolus release at the site of the infection and then prevent re-infection through a further controlled ...
"BARDA has offered strong support in the development of the Selux NGP platform and has led the way in the successful government-private sector collaboration to solve one of the world's toughest health challenges -- antibiotic resistance," said Steve Lufkin, CEO at Selux. "This leadership is especially vital now, as new data indicate the antibiotic resistance ...